



WHAT IS CLAIMED IS:

1. A composition comprising:
 - a) at least one physiologically tolerated film-forming agent;
 - b) at least one physiologically tolerated solvent;
 - c) at least one plasticizer; and
 - d) a compound of the formula I



or a stereoisomeric form or a physiologically tolerated salt of any of the foregoing, in which:

- | | | |
|-------------------|-----|--|
| R ¹ is | 1) | -CN, |
| | 2) | -NO ₂ , |
| | 3) | a halogen, or |
| | 4) | (C ₁ -C ₄)-alkyl-C(O)-OH; |
| R ² is | 1) | -CF ₃ , |
| | 2) | a halogen, or |
| | 3) | -CN; |
| R ³ is | 1) | =O, |
| | 2) | =S, or |
| | 3) | =NH; |
| X is | -1) | a radical of formula II |




or

2) a radical of formula III



or X and Y together form a group of formula IV




in which R⁴ is

- 1) hydrogen atom,
- 2) (C₁-C₆)-alkyl-,
- 3) (C₂-C₆)-alkenyl-, or
- 4) (C₁-C₆)-alkyl-,

wherein the alkyl is mono- to trisubstituted by

- 4.1 -OH,
- 4.2 halogens,
- 4.3 -O-(C₁-C₄)-alkyl,
- 4.4 -CN, or
- 4.5 -SH;

Y is 1) a radical of formula V




in which:

R⁵ is, independently of R⁶, a hydrogen atom or (C₁-C₄)-alkyl, wherein the alkyl is unsubstituted or mono- to tetrasubstituted by halogens, and

R^6 is, independently of R^5 , (C_1-C_4) -alkyl, wherein the alkyl is unsubstituted or mono- to trisubstituted, by


- a) halogens,
- b) phenyl- $(CH_2)_m$ -, wherein the phenyl is unsubstituted or mono- to trisubstituted, independently of one another, by -COOH, -CN, or -CF₃, and m is the integer zero, 1, 2, 3, 4, 5, or 6,
- c) -COOH,
- d) -CN, or
- e) -CF₃, or

2) a radical of formula VI,



in which R^4 is as defined above; and

- Z is
- 1) -O- or
 - 2) a radical of formula VII



2. A composition as claimed in claim 1, wherein the compound of formula I is a compound in which:

R¹ is 1) -CN,
2) -NO₂, or
3) a halogen;

R² is 1) -CF₃ or
2) a halogen;

R³ is 1) =O or
2) =S;

X is the radical of formula II or III, or

X and Y together form the group of formula IV,
in which R⁴ is as defined in claim 1;

Y is the radical of formula VI,
in which R⁴ is as defined in claim 1; and

Z is the radical of formula VII.

3. A composition as claimed in claim 1, wherein the compound of formula I is a compound in which:

R¹ is -CN;

R² is -CF₃;

R³ is =O;

X is the radical of formula II;

Y is the radical of formula VI, in which R⁴ is hydrogen; and

Z is -O- or the radical of formula VII.

4. A composition as claimed in claim 1, wherein the compound of formula I is chosen from 4-[3-(4-hydroxybutyl)-4,4-dimethyl-2,5-dioxo-1-imidazolidinyl]-2-(trifluoromethyl)benzonitrile and 4-(5-

methyl-2,4-dioxo-5-trifluoromethyl)-oxazolidin-3-yl)-2-(trifluoromethyl)-benzonitrile.

5. A composition as claimed in claim 1, wherein the at least one plasticizer is chosen from ethoxylated compounds, panthenol, esters of adipic acid, and esters of sebacic acid.
6. A composition as claimed in claim 5, wherein the at least one plasticizer is chosen from polyoxyethylated castor oil, ethoxylated cholesterol, and panthenol.
7. A composition as claimed in claim 1, wherein the at least one physiologically tolerated solvent is chosen from water and (C₁-C₆)-alcohols.
8. A composition as claimed in claim 7, wherein the (C₁-C₆)-alcohols are chosen from methanol, ethanol, propanol, isopropanol, butanol, pentanol, and hexanol.
9. A composition as claimed in claim 1, wherein the at least one physiologically tolerated film-forming agent comprises at least one naturally occurring substance chosen from alginic acid, alginates, collagen, collagen derivatives, hydrolyzed wheat proteins, carrageenan, cellulose, cellulose derivatives, chitosan, chitosan derivatives, keratin hydrolysates, protein hydrolysates, gelatin, guar gum, guar gum derivatives, hydrolyzed elastin, hydrolyzed milk proteins, hydrolyzed silk proteins, hydrolyzed soya proteins, hydrolyzed oat proteins, copolymers of

10

hydroxyethylcellulose, dimethyldiallylammonium chloride,
hyaluronic acid, hyaluronates, tragacanth, and xanthan.

10. A composition as claimed in claim 1, wherein the at least one physiologically tolerated film-forming agent comprises at least one synthetic substance chosen from acrylate/acrylamide copolymers, acrylate copolymers, acrylate/octylacrylamide copolymers, acrylic acid ester copolymers, methacrylic acid copolymers, adipic acid/dimethyl-aminohydroxypropyldiethylenetriamine copolymers, methacrylic acid/methacrylic acid ester copolymers neutralized with 2-amino-2-methylpropanol, polyacrylic acid crosslinked with pentaerythritol ethers or sugar allyl ethers, polysiloxane/polyalkyl polyether copolymers, polysiloxanes, ethylene/acrylic acid ester copolymers, ethylene/vinyl acetate copolymers, methacryloylethylbetaine/methacrylic acid copolymers, octylacrylamide/acrylic acid ester/butylaminoethylmethacrylic acid copolymers, quaternized polyvinylpyrrolidone-dimethylaminoethylmethacrylic acid esters, polyvinylpyrrolidone/imidazolinium methochloride copolymers, sodium acrylate/dimethyldiallylammonium chloride copolymers, dimethyldiallylammonium chloride/sodium acrylate/acrylamide terpolymers, poly(dimethylsiloxane-copolyol-phospho-panthanoate), poly(methyl vinyl ether-maleic anhydride), poly(methyl vinyl ether-maleic acid monoalkyl ester), poly(vinylpyrrolidone), terpolymers based on pyrrolidone and acrylic acid compounds, poly(vinylpyrrolidone-dimethylaminoethylmethacrylic acid), polyvinylpyrrolidone/eicosene copolymers, polyvinylpyrrolidone/methacrylic acid ester/methacrylic acid terpolymers, polyvinylpyrrolidone/hexadecene copolymers, polyvinylpyrrolidone/polycarbamyl polyglycol ester, polyvinylpyrrolidone/vinyl

30

acetate copolymers, vinylimidazolium methochloride/vinylpyrrolidone copolymers, acrylic acid/acrylic acid ester copolymers and terpolymers of vinylpyrrolidone, vinyl acetate, and vinyl propionate.


11. A composition as claimed in claim 1, further comprising at least one additive chosen from circulation-promoting compounds, angiotensin converting enzyme inhibitors, methylxanthine compounds, sodium channel openers, and hair growth-promoting compounds.
12. A composition as claimed in claim 11, wherein at least one circulation-promoting compound is chosen from dihydralazine, diisopropylamine, diazoxide, and calcium antagonists.
13. A composition as claimed in claim 12, wherein at least one calcium antagonist is chosen from nifedipine, nicardipine, verapamil, diltiazem, nisoldipine, nitrendipine, nivaldipine, isradipine, felodipine, nimodipine, gallopamil, fendiline, flunarizine, amlodipine, diperdipine, fluspirilene, primozide, fantofarone, nicergoline, cyclandelate, and 6-amino-4-piperidino-1,2-dihydro-1-hydroxy-2-iminopyrimidine.
14. A composition as claimed in claim 11, wherein at least one angiotensin converting enzyme inhibitor is chosen from quinapril, lisinopril, benzazepril, captopril, ramipril, fosinopril, cifazapril, and trandolapril.

5

15. A composition as claimed in claim 11, wherein at least one methylxanthine compound is chosen from pentoxifyllin, propentofyllin, and torbafyllin.
16. A composition as claimed in claim 11, wherein at least one sodium channel opener is chosen from 1-cyano-2-(1,1-dimethylpropyl)-3-(3-pyridyl)guanidine and 5-alpha-reductase inhibitors.
17. A composition as claimed in claim 16, wherein at least one 5-alpha-reductase inhibitor is N-tert-butyl-3-oxo-4aza-5 α -androst-1-ene-17 β -carboxamide.
18. A composition as claimed in claim 11, wherein at least one hair growth-promoting compound is chosen from inner salts of 2,4-diamino-6-alkoxy-3-sulfoxypyrimidine hydroxide having from 1 to 6 carbon atoms in the alkoxy radical, pyridine 1-oxide compounds, and 2,6-diamino-1,3,5-triazine compounds.
19. A composition as claimed in claim 18, wherein at least one hair growth-promoting compound is an inner salt of 2,4-diamino-6-butoxy-3-sulfoxypyrimidine hydroxide.
20. A composition as claimed in claim 18, wherein at least one pyridine 1-oxide compound is 2,6-diamino-4-piperidinopyridine.
21. A composition as claimed in claim 18, wherein at least one 2,6-diamino-1,3,5-triazine compound is 2,6-diamino-4-butoxy-1,3,5-triazine 1-oxide.

22. A process for making a product for treatment of androgenic alopecia or hirsutism, comprising the step of forming said product by bringing together:

- a) at least one physiologically tolerated film-forming agent;
- b) at least one physiologically tolerated solvent;
- c) at least one plasticizer; and
- d) a compound of the formula I




or a stereoisomeric form or a physiologically tolerated salt of any of the foregoing, in which:

- R^1 is
- 1) -CN,
 - 2) -NO₂,
 - 3) a halogen, or
 - 4) (C₁-C₄)-alkyl-C(O)-OH;

- R^2 is
- 1) -CF₃,
 - 2) a halogen, or
 - 3) -CN;

- R^3 is
- 1) =O,
 - 2) =S, or
 - 3) =NH;


- X is
- 1) a radical of formula II




or

2) a radical of formula III

25



or X and Y together form a group of formula IV



30


in which R^4 is 1) hydrogen atom,
2) $(\text{C}_1\text{--C}_6)\text{-alkyl-}$,
3) $(\text{C}_2\text{--C}_6)\text{-alkenyl-}$, or
4) $(\text{C}_1\text{--C}_6)\text{-alkyl-}$,
wherein the alkyl is mono- to trisubstituted
by

35

- 4.1 -OH ,
- 4.2 halogens,
- 4.3 $\text{-O-(C}_1\text{--C}_4\text{)-alkyl}$,
- 4.4 -CN , or
- 4.5 -SH ;

40

Y is 1) a radical of formula V



in which:

45


R^5 is, independently of R^6 , a hydrogen atom or (C_1-C_4) -alkyl, wherein the alkyl is unsubstituted or mono- to tetrasubstituted by halogens, and R^6 is, independently of R^5 , (C_1-C_4) -alkyl, wherein the alkyl is unsubstituted or mono- to trisubstituted, by

50

- a) halogens,
- b) phenyl- $(CH_2)_m$, wherein the phenyl is unsubstituted or mono- to trisubstituted, independently of one another, by -COOH, -CN, or -CF₃, and m is the integer zero, 1, 2, 3, 4, 5, or 6,
- c) -COOH,
- d) -CN, or
- e) -CF₃, or


55

- 2) a radical of formula VI,



in which R^4 is as defined above; and


- Z is
- 1) -O- or
 - 2) a radical of formula VII



65

23. A process for making a product intended for treatment of seborrhea or acne, comprising the step of forming said product by bringing together:

- a) at least one physiologically tolerated film-forming agent;
- b) at least one physiologically tolerated solvent;
- c) at least one plasticizer; and
- d) a compound of the formula I



or a stereoisomeric form or a physiologically tolerated salt of any of the


foregoing, in which:

- R¹ is
- 1) -CN,
 - 2) -NO₂,
 - 3) a halogen, or
 - 4) (C₁-C₄)-alkyl-C(O)-OH;

- R² is
- 1) -CF₃,
 - 2) a halogen, or
 - 3) -CN;

- R³ is
- 1) =O,
 - 2) =S, or
 - 3) =NH;

- X is
- 1) a radical of formula II




or

2) a radical of formula III




or X and Y together form a group of formula IV



in which R^4 is 1) hydrogen atom,
2) $(\text{C}_1\text{-C}_6)\text{-alkyl-}$,
3) $(\text{C}_2\text{-C}_6)\text{-alkenyl-}$, or
4) $(\text{C}_1\text{-C}_6)\text{-alkyl-}$,
wherein the alkyl is mono- to
trisubstituted by

- 4.1 -OH ,
- 4.2 halogens,
- 4.3 $\text{-O-(C}_1\text{-C}_4\text{)-alkyl}$,
- 4.4 -CN , or
- 4.5 -SH ;

Y is 1) a radical of formula V




in which:

R^5 is, independently of R^6 , a hydrogen atom or (C_1-C_4) -alkyl, wherein the alkyl is unsubstituted or mono- to tetrasubstituted by halogens, and R^6 is, independently of R^5 , (C_1-C_4) -alkyl, wherein the alkyl is unsubstituted or mono- to trisubstituted, by


- a) halogens,
- b) phenyl- $(CH_2)_m$ -, wherein the phenyl is unsubstituted or mono- to trisubstituted, independently of one another, by -COOH, -CN, or -CF₃, and m is the integer zero, 1, 2, 3, 4, 5, or 6,
- c) -COOH,
- d) -CN, or
- e) -CF₃, or

2) a radical of formula VI,




in which R^4 is as defined above; and

- Z is
- 1) -O- or
 - 2) a radical of formula VII



24. A process for treatment of androgenic alopecia or hirsutism, comprising the step of applying to a patient in need or desire thereof a composition comprising:

- a) at least one physiologically tolerated film-forming agent;
- b) at least one physiologically tolerated solvent;
- c) at least one plasticizer; and
- d) a compound of the formula I




or a stereoisomeric form or a physiologically tolerated salt of any of the foregoing, in which:

- R^1 is
- 1) -CN,
 - 2) -NO₂,
 - 3) a halogen, or
 - 4) (C₁-C₄)-alkyl-C(O)-OH;

- R^2 is
- 1) -CF₃,
 - 2) a halogen, or
 - 3) -CN;


- R^3 is
- 1) =O,
 - 2) =S, or
 - 3) =NH;

- X is
- 1) a radical of formula II




or

2) a radical of formula III




or X and Y together form a group of formula IV



in which R^4 is 1) hydrogen atom,
2) $(\text{C}_1\text{-C}_6)\text{-alkyl-}$,
3) $(\text{C}_2\text{-C}_6)\text{-alkenyl-}$, or
4) $(\text{C}_1\text{-C}_6)\text{-alkyl-}$,
wherein the alkyl is mono- to
trisubstituted by

- 4.1 -OH,
- 4.2 halogens,
- 4.3 -O-($\text{C}_1\text{-C}_4$)-alkyl,
- 4.4 -CN, or
- 4.5 -SH;

Y is 1) a radical of formula V



in which:

45

R^5 is, independently of R^6 , a hydrogen atom or (C_1-C_4) -alkyl, wherein the alkyl is unsubstituted or mono- to tetrasubstituted by halogens, and R^6 is, independently of R^5 , (C_1-C_4) -alkyl, wherein the alkyl is unsubstituted or mono- to trisubstituted, by


50

- a) halogens,
- b) phenyl- $(CH_2)_m$ -, wherein the phenyl is unsubstituted or mono- to trisubstituted, independently of one another, by -COOH, -CN, or -CF₃, and m is the integer zero, 1, 2, 3, 4, 5, or 6,
- c) -COOH,
- d) -CN, or
- e) -CF₃, or

55


60

- 2) a radical of formula VI,



in which R^4 is as defined above; and

- Z is
- 1) -O- or
 - 2) a radical of formula VII




65

25. The process as claimed in claim 24, wherein said composition is applied to keratin fibers.
26. The process according to claim 25, wherein said fibers are human fibers.
27. The process according to claim 25, wherein said fibers are human hair.


28. A process for treatment of seborrhea or acne, comprising the step of applying to a patient in need or desire thereof a composition comprising:

- a) at least one physiologically tolerated film-forming agent;
- b) at least one physiologically tolerated solvent;
- c) at least one plasticizer; and
- d) a compound of the formula I




or a stereoisomeric form or a physiologically tolerated salt of any of the foregoing, in which:

- | | |
|-------------------|---|
| R ¹ is | 1) -CN, |
| | 2) -NO ₂ , |
| | 3) a halogen, or |
| | 4) (C ₁ -C ₄)-alkyl-C(O)-OH; |
| R ² is | 1) -CF ₃ , |
| | 2) a halogen, or |
| | 3) -CN; |
| R ³ is | 1) =O, |
| | 2) =S, or |
| | 3) =NH; |
| X is | 1) a radical of formula II |




or

2) a radical of formula III




or X and Y together form a group of formula IV



in which R^4 is 1) hydrogen atom,
2) $(\text{C}_1\text{-C}_6)\text{-alkyl-}$,
3) $(\text{C}_2\text{-C}_6)\text{-alkenyl-}$, or
4) $(\text{C}_1\text{-C}_6)\text{-alkyl-}$,
wherein the alkyl is mono- to
trisubstituted by

- 4.1 -OH,
- 4.2 halogens,
- 4.3 $-\text{O}-(\text{C}_1\text{-C}_4)\text{-alkyl}$,
- 4.4 -CN, or
- 4.5 -SH;

Y is 1) a radical of formula V




in which:

R^5 is, independently of R^6 , a hydrogen atom or (C₁-C₄)-alkyl, wherein the alkyl is unsubstituted or mono- to tetrasubstituted by halogens, and R^6 is, independently of R^5 , (C₁-C₄)-alkyl, wherein the alkyl is unsubstituted or mono- to trisubstituted, by


- a) halogens,
- b) phenyl-(CH₂)_m-, wherein the phenyl is unsubstituted or mono- to trisubstituted, independently of one another, by -COOH, -CN, or -CF₃, and m is the integer zero, 1, 2, 3, 4, 5, or 6,
- c) -COOH,
- d) -CN, or
- e) -CF₃, or

- 2) a radical of formula VI,




in which R^4 is as defined above; and

- Z is
- 1) -O- or
 - 2) a radical of formula VII




29. A cosmetic composition comprising:
- a) at least one physiologically tolerated film-forming agent;
 - b) at least one physiologically tolerated solvent;
 - c) at least one plasticizer; and
 - d) a compound of the formula I



or a stereoisomeric form or a physiologically tolerated salt of any of the foregoing, in which:

- R^1 is
- 1) -CN,
 - 2) -NO₂,
 - 3) a halogen, or
 - 4) (C₁-C₄)-alkyl-C(O)-OH;
- R^2 is
- 1) -CF₃,
 - 2) a halogen, or
 - 3) -CN;
- R^3 is
- 1) =O,
 - 2) =S, or
 - 3) =NH;
- X is
- 1) a radical of formula II




or

2) a radical of formula III




or X and Y together form a group of formula IV



in which R^4 is 1) hydrogen atom,
2) $(\text{C}_1\text{--C}_6)\text{-alkyl-}$,
3) $(\text{C}_2\text{--C}_6)\text{-alkenyl-}$, or
4) $(\text{C}_1\text{--C}_6)\text{-alkyl-}$,
wherein the alkyl is mono- to
trisubstituted by

- 4.1 -OH ,
- 4.2 halogens,
- 4.3 $\text{-O-(C}_1\text{--C}_4\text{)-alkyl}$,
- 4.4 -CN , or
- 4.5 -SH ;

Y is 1) a radical of formula V




in which:

R^5 is, independently of R^6 , a hydrogen atom or $(\text{C}_1\text{--C}_4)\text{-alkyl}$, wherein the alkyl is unsubstituted or mono- to tetrasubstituted by halogens, and

R^6 is, independently of R^5 , (C_1-C_4) -alkyl, wherein the alkyl is unsubstituted or mono- to trisubstituted, by

- a) halogens,
- b) phenyl- $(CH_2)_m$ -, wherein the phenyl is unsubstituted or mono- to trisubstituted, independently of one another, by -COOH, -CN, or -CF₃, and m is the integer zero, 1, 2, 3, 4, 5, or 6,
- c) -COOH,
- d) -CN, or
- e) -CF₃, or

2) a radical of formula VI,



in which R^4 is as defined above; and

- Z is
- 1) -O- or
 - 2) a radical of formula VII

